GL 101Alternative Names: GL101
Latest Information Update: 10 Feb 2016
At a glance
- Originator Glia LLC.
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Corneal disorders
Most Recent Events
- 01 Jan 2016 Phase-II clinical trials in Corneal disorders (Treatment-experienced) in USA (Topical) (NCT02656394)